Solid Biosciences to Present SGT-003 Duchenne Gene Therapy Research at ESGCT 2026

By Public Technologies
  • Solid Biosciences will present seven research posters at the ESGCT congress in Hamburg, Germany, October 27-30, 2026.
  • SGT-003 findings scheduled for October 28 describe restored muscle-protein complex stability and improved muscle integrity in Duchenne muscular dystrophy.
  • October 29 presentations cover improved POLARIS-101 gene delivery, including successful delivery to multiple tissues following depletion of preexisting antibodies.
  • Manufacturing research scheduled for October 28-29 focuses on increasing viral vector yields, improving quality and scaling production.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Solid Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610200800PRIMZONEFULLFEED9849184) on October 20, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk